Title: CETP set-back, again.
Authors: Mullard, Asher
Abstract: The article reports that pharmaceutical firm Eli Lilly has cancelled the Phase III trial of the cholesteryl ester transfer protein (CETP) inhibitor drug evacetrapib after an analysis revealed a low-effectiveness of the drug in treating atherosclerosis.
Subjects: CHOLESTERYL ester transfer protein; DRUG efficacy; ATHEROSCLEROSIS treatment; CLINICAL trials; MEDICAL research
Publication: Nature Reviews Drug Discovery, 2015, Vol 14, Issue 11, p739
ISSN: 1474-1776
Publication type: Academic Journal
DOI: 10.1038/nrd4781

CETP set-back, again.

Mullard, Asher